Scripps Research Logo

Daniel Hoyer, Ph.D.

Professor Adjunct
Department of Molecular Medicine
California Campus
Scripps VIVO Scientific Profile
dhoyer@scripps.edu
(858) 784-8402

Education

D.Sc. (Pharmacology), Louis Pasteur University 1981
Ph.D. (Pharmacology), Louis Pasteur University 1981

Professional Experience

2004-2017 Professor Adjunct, Chemical Physiology, The Scripps Research Institute
1983-2012 Director, Novartis leading scientist, Neuropsychiatry, Neuroscience research, Novartis
2003-2005 Director of Translational Biology, Neuropsychiatry, Novartis
2002-2005 Member Core Management Team, Neuroscience Research, NIBR Basel, Novartis
1981-1983 Postdoctoral Research Associate, Medical School, Pharmacology, University of Pennsylvania

Selected References

All Publications

Curtis, M. J., Alexander, S., Cirino, G., Docherty, J. R., George, C. H., Giembycz, M. A., Hoyer, D., Insel, P. A., Izzo, A. A., Ji, Y., MacEwan, D. J., Sobey, C. G., et al. Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers. (2018). British Journal of Pharmacology, 175(7), 987-993. PMCID: PMC5843711.

Velkov, T., Dai, C., Ciccotosto, G. D., Cappai, R., Hoyer, D. & Li, J. Polymyxins for CNS infections: Pharmacology and neurotoxicity. (2018). Pharmacology & Therapeutics, 181, 85.

Hoyer, D. 5-HT receptor nomenclature: Naming names, does it matter? A tribute to Maurice Rapport. (2017). ACS Chemical Neuroscience, 8(5), 908-919.

Palacios, J. M., Pazos, A. & Hoyer, D. A short history of the 5-HT2C receptor: From the choroid plexus to depression, obesity and addiction treatment. (2017). Psychopharmacology, 234(9-10), 1395-1418.

Jacobson, L. H., Hoyer, D., Fehlmann, D., Bettler, B., Kaupmann, K. & Cryan, J. F. Blunted 5-HT1A receptor-mediated responses and antidepressant-like behavior in mice lacking the GABA(B1a) but not GABA(B1b) subunit isoforms. (2017). Psychopharmacology, 234(9-10), 1511-1523.

Liddelow, S. & Hoyer, D. Astrocytes: adhesion molecules and immunomodulation. (2016). Current Drug Targets, 17(16), 1871-1881.

Andreetta, F., Carboni, L., Grafton, G., Jeggo, R., Whyment, A. D., van den Top, M., Hoyer, D., Spanswick, D. & Barnes, N. M. Hippocampal 5-HT7 receptors signal phosphorylation of the GluA1 subunit to facilitate AMPA receptor mediated-neurotransmission in vitro and in vivo. (2016). British Journal of Pharmacology, 173(9), 1438-1451. PMCID: PMC4831309.

Steckler, T., Curran, H. V., de Wit, H., Howes, O., Hoyer, D., Lucki, I., Miczek, K. A., Morrow, A. L., Price, L. H. & Robbins, T. W. Reporting guidelines for psychopharmacology. (2016). Psychopharmacology, 233(7), 1131-1134.

Feuerbach, D., Pezous, N., Weiss, M., Shakeri-Nejad, K., Lingenhoehl, K., Hoyer, D., Hurth, K., Bilbe, G., Pryce, C. R., McAllister, K., Chaperon, F., Kucher, K., et al. AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation. (2015). British Journal of Pharmacology, 172(5), 1292-1304. PMCID: PMC4337702.

Behnke, D., Cotesta, S., Hintermann, S., Fendt, M., Gee, C. E., Jacobson, L. H., Laue, G., Meyer, A., Wagner, T., Badiger, S., Chaudhari, V., Chebrolu, M., et al. Discovery of 1H-pyrazolo 3,4-b pyridines as potent dual orexin receptor antagonists (DORAs). (2015). Bioorganic & Medicinal Chemistry Letters, 25(23), 5555-5560.